Ga offline met de app Player FM !
Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre
Manage episode 390589137 series 3369804
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
52 afleveringen
Manage episode 390589137 series 3369804
In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
Here are the abstracts that were discussed:
Mantle Cell Lymphoma
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
https://ash.confex.com/ash/2023/webprogram/Paper191921.html
Chronic Lymphocytic Leukemia
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
Hodgkin Lymphoma
1. S1826 outcomes in older adults:
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
Diffuse Large B-cell Lymphoma
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
52 afleveringen
सभी एपिसोड
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.